Figure 5.

Prevalence of glucose intolerance and T2D in PCOS. The prevalence of IGT and T2D in four large multiethnic PCOS cohorts is substantially increased. The true prevalence of diabetes was likely underestimated in these studies because diagnosed women with type 1 or type 2 diabetes were not included in the cohorts. NGT, Normal glucose tolerance.* [The University of Chicago data were reported by D. A. Ehrmann et al.: Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22:141–146, 1999 (124), with permission. © American Diabetes Association.** The Penn State University and Mt. Sinai data were reported by R. S. Legro et al.: Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84:165–169, 1999 (123), with permission. © The Endocrine Society.*** The Rezulin (troglitazone) Collaborative Group data were reported by R. Azziz et al.: Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 86:1626–1632, 2001 (392), with permission. © The Endocrine Society.] The figure is used with the permission of David Ehrmann.